This Centre seeks to understand the molecular basis for lymphoma, leukaemia and myeloma to identify targets for novel targeted therapies and to identify biomarkers of prognosis and response to treatment. We also seek to understand the impact of the tumour microenvironment on malignant cell survival and resistance to therapy. A long-standing strength has been the translational components with strong links to the clinic through clinical senior lecturers and clinical research fellowships and high enrolment of patients in clinical trials.
Welcome to the Centre for Haemato-Oncology, where our main mission is to find cures for haematologic malignancies. We are a centre of excellence in state-of-the-art research and clinical translation, which brings together internationally-recognised basic scientists with top clinical academics.
Our central aim is to understand the biology of leukaemias and lymphomas and harness this knowledge to identify new treatment strategies. Working closely together with the Haemato-oncology department at the St Bartholomew’s Hospital Cancer Centre we are uniquely well placed to implement our findings in clinical practice. Moreover, our Centre is embedded in Queen Mary’s Faculty of Medicine and Dentistry, one of the UK’s top medical schools, thus offering excellent opportunities for multidisciplinary collaborations.
Our main research themes and their associated faculty include:
Centre Lead
Deputy Centre Lead
John Vane Science Centre,
Charterhouse Square,
London EC1M 6BQ
Professor of Genome Regulation
Reader in Haemato-oncology and Honorary Consultant
Senior Lecturer
Clinical Reader
Clinical Reader in Experimental Haematology
Reader in Haematopoietic Stem Cell Biology
Professor of Medical Oncology
Senior Lecturer
Professor of Translational Cancer Research
Clinical Reader in Cancer Immuno-metabolism
Reader in Stem Cell Biology and Disease
Clinical Senior Lecturer
Researchers have been awarded £1m to launch a new clinical trial for people with myelodysplastic syndromes, a form of blood cancer with limited treatment options.
Publications 8 April 2026
Molecules exhaled in the breath may provide clues to detect blood cancer, according to new research by scientists at Barts Cancer Institute. The findings could enable the development of a blood cancer breathalyser, providing a rapid, low-cost way to detect disease.
General News 23 July 2025
Researchers have discovered a new mechanism by which B cells – antibody-producing immune cells – use a cellular recycling process called autophagy to control changes to their DNA essential for antibody improvement. The findings could have future implications for the development of certain blood cancers and autoimmune diseases.
General News 2 July 2025